NasdaqGS:OVID

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$289.5m

Last Updated

2021/06/22 02:05 UTC

Data Sources

Company Financials +

Executive Summary

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. More Details


Snowflake Analysis

Flawless balance sheet and undervalued.

Share Price & News

How has Ovid Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: OVID is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: OVID's weekly volatility has decreased from 13% to 7% over the past year.


Market Performance


7 Day Return

-4.0%

OVID

-1.9%

US Biotechs

-1.0%

US Market


1 Year Return

-41.3%

OVID

20.0%

US Biotechs

39.0%

US Market

Return vs Industry: OVID underperformed the US Biotechs industry which returned 18.9% over the past year.

Return vs Market: OVID underperformed the US Market which returned 38.2% over the past year.


Shareholder returns

OVIDIndustryMarket
7 Day-4.0%-1.9%-1.0%
30 Day8.4%3.8%2.0%
90 Day7.6%4.4%6.0%
1 Year-41.3%-41.3%21.7%20.0%41.2%39.0%
3 Year-49.0%-49.0%11.0%6.4%61.3%51.3%
5 Yearn/a65.3%52.2%133.8%107.4%

Long-Term Price Volatility Vs. Market

How volatile is Ovid Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Ovid Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: OVID ($4.37) is trading below our estimate of fair value ($53.9)

Significantly Below Fair Value: OVID is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: OVID is good value based on its PE Ratio (2.5x) compared to the US Biotechs industry average (23.6x).

PE vs Market: OVID is good value based on its PE Ratio (2.5x) compared to the US market (18.9x).


Price to Earnings Growth Ratio

PEG Ratio: OVID's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: OVID is good value based on its PB Ratio (1.3x) compared to the US Biotechs industry average (3.4x).


Future Growth

How is Ovid Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

-60.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OVID's earnings are forecast to decline over the next 3 years (-60.7% per year).

Earnings vs Market: OVID's earnings are forecast to decline over the next 3 years (-60.7% per year).

High Growth Earnings: OVID's earnings are forecast to decline over the next 3 years.

Revenue vs Market: OVID's revenue is expected to decline over the next 3 years (-41.5% per year).

High Growth Revenue: OVID's revenue is forecast to decline over the next 3 years (-41.5% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OVID's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Ovid Therapeutics performed over the past 5 years?

4.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OVID has high quality earnings.

Growing Profit Margin: OVID became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: OVID has become profitable over the past 5 years, growing earnings by 4% per year.

Accelerating Growth: OVID has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: OVID has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).


Return on Equity

High ROE: OVID's Return on Equity (52%) is considered outstanding.


Financial Health

How is Ovid Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: OVID's short term assets ($236.7M) exceed its short term liabilities ($16.3M).

Long Term Liabilities: OVID has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: OVID is debt free.

Reducing Debt: OVID has not had any debt for past 5 years.

Debt Coverage: OVID has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: OVID has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Ovid Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OVID's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OVID's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OVID's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OVID's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OVID's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.4yrs

Average management tenure


CEO

Jeremy Levin (67 yo)

6.25yrs

Tenure

US$2,135,499

Compensation

Dr. Jeremy Max Levin, BA Zoology, DPhil, MB BChir, has been the Chief Executive Officer of Ovid Therapeutics Inc. since March 2015 and serves as its Executive Director. From 1996 to 2000, Dr. Levin has exp...


CEO Compensation Analysis

Compensation vs Market: Jeremy's total compensation ($USD2.14M) is above average for companies of similar size in the US market ($USD1.07M).

Compensation vs Earnings: Jeremy's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: OVID's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: OVID's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 23.8%.


Top Shareholders

Company Information

Ovid Therapeutics Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ovid Therapeutics Inc.
  • Ticker: OVID
  • Exchange: NasdaqGS
  • Founded: 2014
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$289.537m
  • Shares outstanding: 67.81m
  • Website: https://www.ovidrx.com

Number of Employees


Location

  • Ovid Therapeutics Inc.
  • 1460 Broadway
  • Suite 15021
  • New York
  • New York
  • 10036
  • United States

Listings


Biography

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candida...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/22 02:05
End of Day Share Price2021/06/21 00:00
Earnings2021/03/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.